How NAD+ works, and what the precursor trials measured

Start here

NAD+ does two jobs in a cell. First, it is a redox (chemistry that shuttles electrons to release energy) carrier: it picks up electrons from food breakdown and hands them to the machinery that makes ATP, the cell's energy currency. Second, it is a consumable fuel for repair-and-maintenance enzymes that fix DNA and tune inflammation. Because those enzymes use NAD+ up, and because the cell's NAD+ supply drops with age, scientists have tested whether feeding the body NAD+ precursors (NMN, NR) restores the supply. This page walks through that mechanism and then the human precursor trials, lightest claims flagged as such.

NAD+ as the cell's redox coenzyme

NAD+ cycles between an oxidized form (NAD+) and a reduced form (NADH). In catabolism it accepts electrons to become NADH; in the mitochondrial electron transport chain NADH donates them to drive ATP synthesis. This redox cycling runs through glycolysis, the TCA cycle, and oxidative phosphorylation, which makes NAD+ a coenzyme for hundreds of oxidoreductase reactions ^[5].

Beyond redox, NAD+ is a consumed substrate. A foundational review identifies the major NAD-consuming enzymes — sirtuins (SIRT1-7), PARPs (chiefly PARP1), and CD38/CD157 — that compete for a shared, finite NAD+ pool, and frames restoring NAD+ as a candidate strategy against age-related disease ^[5]. When NAD+ is consumed by signaling, it must be resynthesized, which is why the supply routes matter as much as the demand.

How the body makes NAD+: salvage, NRK, and de novo routes

Mammals make NAD+ by three main routes. The dominant one is the salvage pathway, which recycles nicotinamide back into NAD+ via NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme, producing NMN, which NMNAT then converts to NAD+ ^[5]. A second route, used by NR, runs nicotinamide riboside through the NRK1/NRK2 kinases to NMN and then to NAD+, bypassing NAMPT. The third is de novo synthesis from tryptophan, with the Preiss-Handler pathway feeding in from nicotinic acid ^[5].

These routes are the reason precursor supplements work at all: an oral precursor enters one of these pathways and is converted to NAD+ downstream, raising the measurable pool ^[4].

NMN (Nicotinamide Mononucleotide): The Most-Studied Oral NAD+ Precursor

NMN is a direct NAD+ precursor one biochemical step from NAD+, and it has the strongest body of human trial data among the precursors. In a randomized trial in prediabetic, postmenopausal women, 250 mg/day of oral NMN for 10 weeks significantly increased muscle insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp) and remodeled insulin signaling, with no change in body composition or HbA1c ^[1]. In a multicenter, double-blind, placebo-controlled trial in healthy middle-aged adults, NMN at 300, 600, or 900 mg/day for 60 days dose-dependently raised blood NAD+ at days 30 and 60 (p ≤ 0.001 across all NMN groups), improved walking distance, and identified 600 mg/day as the optimal dose among those tested, with no safety issues at any dose ^[3].

NMN's regulatory status is contested: the FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was investigated as a drug — a marketplace dispute, not a determination that NMN is illegal to possess ^[10]. The trials above measured blood NAD+, insulin sensitivity, and physical performance; none demonstrated treatment of any disease.

Nicotinamide Riboside (NR): A Well-Tolerated, Dose-Scalable NAD+ Booster

Nicotinamide riboside is a vitamin-B3-family precursor converted to NMN by the NRK kinases, then to NAD+. In a randomized, double-blind, placebo-controlled trial in healthy overweight adults, NR at 100, 300, and 1000 mg/day for 8 weeks raised whole-blood NAD+ by 22%, 51%, and 142% respectively — a dose-dependent elevation maintained throughout the study, with no flushing and no significant adverse-event differences from placebo at any dose ^[4]. NR did not elevate LDL cholesterol or disrupt one-carbon metabolism, which supports its profile as a dose-scalable oral NAD+ booster ^[4].

A 14-day randomized trial comparing NR, NMN, nicotinamide, and placebo found both NR and NMN increased whole-blood NAD+ roughly 2-fold versus placebo (differences of ~49 µM and ~43 µM; p < 0.001), while NAM had no significant effect; the trial also reported that the gut microbiome converts NR and NMN to nicotinic acid, which may mediate part of the NAD+ boost ^[13].

The consumer enzymes: sirtuins, PARP1, and CD38

Three enzyme families consume NAD+ and explain why its supply matters. Sirtuins (SIRT1-7) are NAD+-dependent deacylases that regulate metabolism, stress resistance, and DNA repair ^[5]. PARP1 is a DNA-repair enzyme that consumes large amounts of NAD+ when activated by DNA damage; in reconstitution biochemistry, PARP1 inhibited mitochondrial DNA polymerase Pol γ when NAD+ was absent and allowed full repair activity as NAD+ rose to physiological levels, coupling mitochondrial DNA repair to the cellular NAD+ state ^[8]. A review of PARP1/ARTD1 activation describes NAD+ as the limiting substrate that links DNA repair to energy depletion and, when PARP1 over-activates, to cell death relevant to cancer, inflammation, and ischaemia/reperfusion ^[7].

CD38 is the principal NAD-consuming ectoenzyme whose activity rises with age. In mice, CD38 deletion preserves NAD+ and SIRT3 activity and improves mitochondrial and metabolic health with age, identifying CD38 as a key driver of the age-related NAD+ decline ^[2]. Senescent cells amplify this: they increase CD38 expression via their secretory phenotype, creating a feedback loop that depletes tissue NAD+ during aging, and NMN supplementation in aged mice reduced markers of cellular senescence ^[14]. In inflammatory contexts, activated macrophages become dependent on NAMPT-driven NAD+ salvage after ROS-mediated DNA damage consumes NAD+ through PARP ^[6], and NAD+ metabolism more broadly regulates immune function and inflammageing ^[9].

Does NAD make you look younger?

No study shows NAD+ or its precursors make people look younger. Much of the strongest anti-aging data come from rodents, and a 2025 Nature Metabolism review concluded human efficacy for hard clinical endpoints remains preliminary ^[10]. NAD+ supports cellular metabolism; it is not a cosmetic treatment, and no cited trial measured appearance.

Does NAD help with weight loss?

No cited trial demonstrates weight loss from NAD+ or its precursors. In the NMN insulin-sensitivity trial, 250 mg/day for 10 weeks improved muscle insulin sensitivity but produced no change in body composition ^[1]. The human evidence centers on blood NAD+, insulin signaling, and physical performance, not fat loss.

Does NAD cause weight gain?

No cited trial reported weight gain from NAD+ precursors. The 10-week NMN insulin-sensitivity trial found no change in body composition or HbA1c ^[1]. Effects in the controlled studies centered on insulin sensitivity and physical performance rather than body weight.

Does NAD help with fertility?

The studies summarized in this digest do not test fertility endpoints. The human evidence here centers on blood NAD+ elevation, muscle insulin sensitivity, and physical performance ^[1][3][4]; no fertility claim can be supported from these citations.

Is taking NAD orally effective?

Oral NAD+ itself is poorly taken up by cells intact, so most researchers consider the precursors NMN and NR the rational oral approach ^[10]. In randomized trials, oral NR raised whole-blood NAD+ by 22/51/142% at 100/300/1000 mg/day ^[4], and oral NMN dose-dependently raised blood NAD+ at 300-900 mg/day ^[3]. Blood-level elevation is well established; clinical-outcome translation is not.